Microdetermination of adrenocortical steroids by double isotope method. 3. Distribution and incorporation of corticosteroids into human blood cell fractions

Wilms tumour

Wilms tumour (WT) is a childhood embryonal tumour that is paradigmatic of the intersection between disrupted organogenesis and tumorigenesis. Many WT genes play a critical (non-redundant) role in early nephrogenesis. Improving patient outcomes requires advances in understanding and targeting of the multiple genes and cellular control pathways now identified as active in WT development. Decades of clinical and basic research have helped to gradually optimize clinical care. Curative therapy is achievable in 90% of affected children, even those with disseminated disease, yet survival disparities within and between countries exist and deserve commitment to change. Updated epidemiological studies have also provided novel insights into global incidence variations. Introduction of biology-driven approaches to risk stratification and new drug development has been slower in WT than in other childhood tumours. Current prognostic classification for children with WT is grounded in clinical and pathological findings and in dedicated protocols on molecular alterations. Treatment includes conventional cytotoxic chemotherapy and surgery, and radiation therapy in some cases. Advanced imaging to capture tumour composition, optimizing irradiation techniques to reduce target volumes, and evaluation of newer surgical procedures are key areas for future research.

Cholesterol sulfate. II. Studies on its metabolism and possible function in canine blood

Previous in vitro studies to evaluate the possible role of cholesterol sulfate in the stabilization of the human erythrocyte membrane have been extended to the dog in vivo. Thus, following the injection of labelled cholesterol sulfate, a large fraction of the administered sterol conjugate is taken up by the membrane of the canine erythrocyte. Peak membrane levels were obtained within 30-60 min. Measurement of radioactivity associated with the plasma and red cell fractions in serial samples allowed the calculation of the half-life of cholesterol sulfate in each fraction. From the data obtained from the plasma of four dogs, the half-life was calculated to 5.8 plus or minus 0.9 h. The half-life of chlesterol sulfate associated with the erythrocyte membrane was calculated to be 6.7 plus or minus 1.2 h. In addition, following the intravenous administration of 0.2-0.7 mg of cholesterol sulfate/kg of body weight and withdrawal of serial blood samples, a significant diminution in the degree of hemolysis was observed when the red cells were exposed to hypotonic saline solutions. Maximal stabilization effects were observed at approx. 6-7 h after the administration of the sterol conjugate. Hemolytic properties returned to normal at approx. 24 h following the injection.